Loading stock data…
SANA
$2.82+0.13 (+4.83%)
After Hours$2.79-0.03 (-1.06%)· Last close Jun 9
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Sana Biotechnology, Inc. in the Healthcare sector is trading at $2.82. Wall Street consensus targets $8.57 (7 analysts), implying a +204.0% move over the next 12 months. The stock is currently near its 52-week low of $2.41, remaining 26.8% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 45/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +204.0% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$2.82
Potential Downside
0%
Whystock Fair Value$2.82
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-202.94%
Volume
Today's trading volume
8.70M
Recent News
Sana Biotech (SANA), Mayo Clinic Partner to Advance Cell Therapy for Type 1 Diabetes
Sana Biotechnology (NASDAQ:SANA) is one of the small cap stocks with the highest upside potential. On April 13, Sana Biotechnology and Mayo Clinic entered into a collaboration to accelerate the development of SC451, an investigational cell replacement therapy for type 1 diabetes. SC451 uses Sana Biotech’s proprietary hypoimmune technology to engineer pancreatic islet cells that […]
Assessing Sana Biotechnology (SANA) Valuation After Mayo Clinic Partnership And Equity Investment
Sana Biotechnology (SANA) is back in focus after Mayo Clinic agreed to collaborate on SC451 for type 1 diabetes and invest up to US$50 million, linking clinical expertise with fresh capital support. See our latest analysis for Sana Biotechnology. The Mayo Clinic collaboration and recent equity raises have arrived alongside a 7.3% 7 day share price return and an 18.3% 30 day share price return, while the 1 year total shareholder return is very large. This suggests that momentum has picked up...
Wedbush Lifts PT on Sana Biotechnology (SANA) to $7 From $6
Sana Biotechnology, Inc. (NASDAQ:SANA) is one of the best stocks under $5 with huge upside potential. Wedbush lifted the price target on Sana Biotechnology, Inc. (NASDAQ:SANA) to $7 from $6 on April 14, reaffirming an Outperform rating on the shares. The firm stated that the company announced a collaboration with the Mayo Clinic to develop […]
Kailera nets $625M in one of biotech’s biggest-ever IPOs
The high-profile obesity drug developer priced the biotech sector’s biggest offering in years and will use the proceeds to support a portfolio of medicines licensed from China’s Hengrui Pharma.
Sana Biotechnology Inc. (SANA) Hits New Milestone on Cell Therapy for Type 1 Diabetes
Sana Biotechnology Inc. (NASDAQ:SANA) is one of the best healthcare penny stocks to buy according to hedge funds. On March 16, H.C. Wainwright reiterated Sana Biotechnology (NASDAQ:SANA) as a Buy with a $7 price target. The research firm remains bullish on the company following the topline clinical trial data presented at the Advanced Technologies & […]